Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

Citation
Schernthaner G, Shehadeh N, Ametov AS, et al. Cardiovasc Diabetol 2020;19:185.